PMID- 29990570
OWN - NLM
STAT- MEDLINE
DCOM- 20181102
LR  - 20181102
IS  - 1873-4863 (Electronic)
IS  - 0168-1656 (Linking)
VI  - 282
DP  - 2018 Sep 20
TI  - Deciphering molecular consequences of the proprotein convertase 1/3 inhibition in 
      macrophages for application in anti-tumour immunotherapy.
PG  - 80-85
LID - S0168-1656(18)30528-5 [pii]
LID - 10.1016/j.jbiotec.2018.07.002 [doi]
AB  - During tumour development, macrophages are recruited to the tumour site and 
      orientated towards an anti-inflammatory phenotype. Due to their immunosuppressive 
      function, tumour associated macrophages (TAMs) are recognized as major components 
      in tumour progression. Changing these macrophages to a pro-inflammatory phenotype 
      is thus extensively studied as a potential means for developing novel anti-tumour 
      therapy. In this context, we found that the Proprotein convertase 1/3 (PC1/3) is 
      a relevant target. Proteomic analysis reveals that PC1/3 knockdown (KD) 
      macrophages present all the characteristic of activated pro-inflammatory 
      macrophages. Moreover, in PC1/3 KD macrophages, TLR4 and TLR9 signaling pathways 
      can be enhanced leading to the secretion of pro-inflammatory factors and 
      anti-tumour factors. To develop an efficient anti-tumour immunotherapy, we may 
      (i) target TAMs directly inside the tumour site for PC1/3 inhibition and TLR 
      activation and used them as "Trojan macrophages" or (ii) directly take advantage 
      of PC1/3 inhibited macrophages and use them as "drone macrophages" by activating 
      them "at distance" with a TLR ligand. Therefore, PC1/3 inhibited macrophages 
      constitute an innovative cell therapy to treat tumours efficiently.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Rodet, Franck
AU  - Rodet F
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France. Electronic address: franck.rodet@univ-lille1.fr.
FAU - Capuz, Alice
AU  - Capuz A
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Hara, Tsukasa
AU  - Hara T
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - van Meel, Rinaldo
AU  - van Meel R
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Duhamel, Marie
AU  - Duhamel M
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Rose, Melanie
AU  - Rose M
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Raffo-Romero, Antonella
AU  - Raffo-Romero A
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Fournier, Isabelle
AU  - Fournier I
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
FAU - Salzet, Michel
AU  - Salzet M
AD  - Inserm U-1192, Laboratoire de Proteomique, Reponse Inflammatoire, Spectrometrie 
      de Masse (PRISM), Universite Lille 1, Cite Scientifique, 59655 Villeneuve D'Ascq, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20180707
PL  - Netherlands
TA  - J Biotechnol
JT  - Journal of biotechnology
JID - 8411927
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Toll-Like Receptor 9)
RN  - EC 3.4.21.93 (Proprotein Convertase 1)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Immunotherapy
MH  - Macrophages/*immunology
MH  - Neoplasms/*therapy
MH  - Proprotein Convertase 1/genetics/*immunology
MH  - Protein Transport
MH  - Signal Transduction
MH  - Toll-Like Receptor 4/immunology
MH  - Toll-Like Receptor 9/immunology
OTO - NOTNLM
OT  - Anti-tumour effect
OT  - Cell therapy
OT  - Macrophages
OT  - Proprotein convertase PC1/3
OT  - TLR4
OT  - TLR9
EDAT- 2018/07/11 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/07/11 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/06/29 00:00 [revised]
PHST- 2018/07/01 00:00 [accepted]
PHST- 2018/07/11 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/07/11 06:00 [entrez]
AID - S0168-1656(18)30528-5 [pii]
AID - 10.1016/j.jbiotec.2018.07.002 [doi]
PST - ppublish
SO  - J Biotechnol. 2018 Sep 20;282:80-85. doi: 10.1016/j.jbiotec.2018.07.002. Epub 
      2018 Jul 7.